GLENMARK PHARMACEUTICALS Financial Ratios
GLENMARK · Healthcare · Current price ₹2,235.5
P/E ratio
46.3x
P/B ratio
5.9x
ROE
30.5%
ROCE
40.0%
Debt / Equity
0.06
Dividend yield
0.1%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 46.3x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.9x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 30.5% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 40.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.06 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with GLENMARK PHARMACEUTICALS's latest numbers.
GLENMARK PHARMACEUTICALS profitability
GLENMARK PHARMACEUTICALS generates a return on equity of 30.5% and a return on capital employed of 40.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.06 and a P/E of 46.3x, GLENMARK PHARMACEUTICALS is conservatively financed. Our overall business-quality score for the company is 5.9 / 10.
Understand the ratios
More on GLENMARK PHARMACEUTICALS
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.